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A B S T R A C T
The goal of our study was to present our long-standing experience of the treatment of prostate carcinoma in patients
over the age of 70. During the 20 years period (from 1991 to 2010) we diagnosed the prostate carcinoma in 1998 patients.
More than 58% of the patients were over 70 years old. The most frequent symptoms of the prostate carcinoma were fre-
quent urination and backache. At the first examination 36% of the patients had both prostate lobes involved, and 27% of
them had metastases. The most frequent ones (26%) were those in the bone system (pelvis and spine), while in only 1%
metastases were found in solid organs (lungs and liver). According to the TNM classification, T1 and T2 were diagnosed
in 818 (71%) patients. Histopathological examination discovered Gleason score 2 in 70% of patients and Gleason score 3
in 24% of them. Most often the combination of castration and antiandrogen therapy (in 68% of the patients) and the com-
bination of castration and Estracyt therapy (in 19% of the patients) were applied. In conclusion, intensified efforts should
be made in promoting preventive urological examinations because of the great number of patients (27%) with metastases
at the first examination.
Key words: antiandrogen therapy, metastasis, prostate carcinoma
Introduction
The Nobel Prize winner Charles Brenton Huggins et
al. laid the groundwork for the hormonal treatment of
the prostate carcinoma in 1941, proving its androgens
dependence1.
Applying castration of the patients, i.e. oestrogen ad-
ministration reducing the level of circulating testoster-
one resulted in dramatic tumour remission in those days.
The initial enthusiasm, concerning the treatment re-
sults, quickly deflated due to ephemeral effects. This cog-
nition resulted in development of additional treatment
strategies such as adrenalectomy, surgical or medica-
mentous hypophysectomy, and production and use of
new antiandrogens, antiprogestins and antiprolactins.
These new additional methods decreased mortality and
morbidity, but did not considerably contribute to the pro-
longation of patients' survivals.
Relatively small number of patients is detected in the
initial stage of the disease, and they undergo radical
treatment, while a greater number of patients show the
signs of locally advanced disease or remote metastases at
the time of making diagnosis. A significant number of pa-
tients with localized prostate carcinoma are not consid-
ered to be good candidates for the radical treatment
because of their old age. Therefore, a large majority of
patients with prostate carcinoma undergoes hormonal
treatment achieving years-long remission of the disease
in the significant number of cases2. However, the full
health recovery is possible only by radical treatment, i.e.
radical prostatectomy or radical radiotherapy. In spite of
remarkable progress in the last decade, the basic proposi-
tions of diagnostics and treatment of the prostate carci-
noma represent a series of negative cognitions even to-
day: aetiology of the disease – unknown; hormonal ther-
apy – palliative; basic diagnostics (palpatory finding and
cytological biopsy) – unchanged in this century; ultra-
sound diagnostics – insufficiently reliable; monitoring
of treatment results – without sufficiently exact param-
eters.
Patients and Methods
The purpose of the study was a prospective monitor-
ing of patients with newly diagnosed prostate carcinoma
at our Department of Urology during 1991–2010 period.
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Diagnostics, treatment and monitoring of patients were
performed in accordance with the existing protocol of the
Croatian Urologic Society. Diagnostic treatment consisted
of digitorectal examination of the prostate, the abdomi-
nal or transrectal ultrasound of the prostate, intrave-
nous urogram, x-ray of the skeleton, cytological trans-
rectal biopsy, PSA analysis, CT and the scintigram of the
skeleton. The clinical stage of the disease was evaluated
on the bases of the results of the above examinations and
expressed in TNM-system3. Tumours were classified ac-
cording to the histological criteria (Gleason score) as well
differentiated (Gleason 1), moderately differentiated (Glea-
son 2) and poorly differentiated (Gleason 3). The basic
treatment of patients over the age of 70 at our depart-
ment is the combination of castration and antiandro-
gens. At the beginning of our study we used castration
and estrogens (Honvan) that were quickly abandoned be-
cause of cardiotoxic effects. Afterwards the Androcur and
Prostandril or Flutamide were most frequently used
with castration. Because of great number of patients
with metastases the combination of castration and Es-
tracyt are very successfully applied in such cases. The
control examinations are done in 3-month intervals. The
control treatment consists of digitorectal examination,
ultrasound of the prostate and the kidneys, PSA analysis
and x-ray of the bones and lungs, as well as scintigraphy
of the skeleton in particular cases4. The shortest observa-
tion time is 6 months and the longest one is 20 years.
During the observation we include in progression of the
disease the appearance of metastases, progression of lo-
cal finding or the increase of the PSA values.
Results
We have discovered 1998 prostate carcinomas during
the aforementioned period (Table 1). The number of
newly detected patients with the prostate carcinoma
with their annual distribution was presented in the Ta-
ble 1. It is evident that most of the new patients were de-
tected in the years 2001–20105. Digitorectal examination
of the prostate has been still the basic diagnostic method
for detecting the prostate carcinoma. In case of suspi-
cious palpatory finding a transrectal needle biopsy of the
prostate follows, being successful in more than 70% of
the patients6. In the last decade the investigations are di-
rected to discover markers of the prostate carcinoma,
like PSA, total and free. PSA was partially determined at
our department of urology during particular time inter-
vals, due to occasional lack of reagent in the course of re-
search. There were 1158 (58%) patients older than 70
years. The dominant symptoms in their clinical picture
were difficulties in urine discharge, backache and reten-
tion of urine. It is interesting that a great number of
patients (26%) sought the medical help for the first time
because of osseous symptoms7. Even 317 patients (27%)
had metastases at the beginning of treatment. Their
localisations were most frequently in the bone system
(26%) and in solid organs (1%). The right prostate lobe
was involved in 34% of our patients and the left one in
30% of them. Both prostate lobes were affected in 36% of
the cases, thus proving the advanced stage of the disease.
For determination of the clinical stage of the disease
we used the classification of the International Associa-
tion for Anti-Cancer Campaign, the so called TNM classi-
fication and histological tumour gradation3. According to
the TNM classification 818 patients developed T1 and T2
of the localised prostate carcinoma and 340 of them had
the advanced carcinoma.
The patients with the localised prostate carcinoma
are presented in the Table 2 according to the stage. The
prevalence of the patients with stages T2c (26%) and T2b
(22%) is evident.
Domination of the T3a stage of the prostate carci-
noma is shown in the Table 3. There were 177 (15%) pa-
tients with this stage.
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TABLE 1
DISTRIBUTION OF 1988 PATIENTS WITH NEWLY DETECTED PROSTATE CARCINOMAS (1991–2010)
Year 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
No. of patients 27 33 60 46 56 75 54 57 59 70
Year 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
No. of patients 137 128 131 148 150 200 191 200 91 85
TABLE 2
PATIENTS WITH LOCALISED PROSTATE CARCINOMA (N=818)







PATIENTS WITH ADVANCED PROSTATE CARCINOMA (N=340)






The prevalence of moderately differentiated prostate
carcinoma is evident in the Table 4. (Gleason 2) in 70% of
the patients3, followed by poorly differentiated carci-
noma (Gleason 3) in 24% of patients, while a well differ-
entiated carcinoma (Gleason 1) was found in only 6% of
them.
It is evident from the Table 5. that the greatest num-
ber of our patients (68%) was treated with combination
of castration and antiandrogen8,9. They were initially ad-
ministered cyproterone acetate and flutamide over last
few years10,11.
Discussion
Metastases were found in great number of patients at
the first examinations. Therefore, they underwent cas-
tration in combination with Estracyt as the therapy12.
This combination was applied in 19% of the patients. It
should be pointed out that we achieved good results with
this medicine and it has been still in use, in spite of its
slow abandonment.
In the first years of this study we used the combina-
tion of castration and oestrogen (Honvan) in 2% of the
patients13.
Radiotherapy is used as radical, adjuvant and pallia-
tive treatment in patients with the prostate carcinoma.
Radical radiotherapy is introduced as the alternative
procedure in patients in T1 and T2 stage of the disease,
being a therapy of choice in T3 and partly in T4 stages of
the disease.
We rarely decided to apply radiotherapy in single
cases of the advanced prostate carcinoma as an adjuvant
and palliative procedure due to particular technical and
organisational problems at the department of radiother-
apy and oncology.
In order to eliminate the obstruction and to create the
„water way“ we carried out TUR of the prostate carci-
noma in only 2% of patients during the first years of this
research. Because of rapid progression of the disease af-
ter TUR, with early lethal outcome in these patients, we
rarely chose TUR of the prostate carcinoma in later
course of the study14.
During the treatment progression of the disease deve-
loped in 182 (16%) patients. The progression was mani-
fested by the increase of the PSA markers and the occur-
rence of metastases. Metastases appeared most frequently
within one year after the initial treatment (112 patients
– 10%).
Conclusion
The prostate carcinoma is a disease of males in their
older age – 1158 patients (58%) in this study were over 70
years old. Metastases were found in the initial treatment in
317 (27%) patients. Diagnostics included digitorectal exam-
ination PBP, PSA, ultrasound, x-ray, scintigraphy of the
skeleton and CT. Greatest number of our patients (68%)
was treated with combination of castration and antian-
drogen8,9. During the treatment progression of the disease
most frequently occurred after one year (112 patients –
10%). There is still a great number of patients with the
prostate carcinoma metastases detected at the first exami-
nation (27%), and intensified efforts should bemade in pro-
moting the preventive urological examinations.
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TABLE 4
CLASSIFICATION OF THE PROSTATE CARCINOMA ACCORDING
TO HISTOLOGICAL CRITERIA





TYPES OF TREATMENT FOR PROSTATE CARCINOMA







Transurethral resection of the carcinoma 21 (1.8%)
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NA[A ISKUSTVA U LIJE^ENJU KARCINOMA PROSTATE U DOBI IZNAD 70 GODINA
S A @ E T A K
Cilj rada je prikazati na{a vi{egodi{nja iskustva u dijagnozi i lije~enju raka prostate kod bolesnika u dobi iznad 70
godina. Tijekom 20 godina (1991.–2010.) kod 1998 bolesnika dijagnosticirali smo karcinom prostate. Vi{e od 58% (1158)
bolesnika bili su u dobi iznad 70 godina. Naj~e{}i simptomi karcinoma prostate bili su u~estalo mokrenje i kri`obolja.
Kod prvog pregleda oko 36% bolesnika imala su zahva}ena oba lobusa prostate, a kod 27% bolesnika na|ene su meta-
staze. Naj~e{}e su metastaze (26%) u ko{tanom sustavu (kosti zdjelice i LS kralje{nica), a samo u 1% bolesnika na{li
smo ih u solidnim organima (plu}a i jetra). Po TNM klasifikaciji stadiji T1 i T2 su dijagnosticirani kod 818 (71%)
bolesnika. Patohistolo{kim pregledom kod 70% bolesnika na|en je Gleason score 2, a Gleason score 3 kod 24%. Naj~e{}e
smo primjenjivali kombinaciju kastracije i antiandrogena (68%) bolesnika i kombinaciju kastracije i Estracyta (19%)
bolesnika. U zaklju~ku mo`emo konstatirati da imamo jo{ uvijek velik broj bolesnika (27%), koji su kod prvog pregleda
ve} imali metastaze,zato moramo poja~ati rad na popularizaciji preventivnih urolo{kih pregleda.
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